GemPharmatech Co

GemPharmatech Co Net Debt per Share

The Net Debt per Share of GemPharmatech Co (688046.SS) as of Oct 21, 2026 is 0.05 CNY. In the previous year, Net Debt per Share was -0.13 CNY — a change of -139.06% (higher).

Net Debt per Share

0.05CNY

YoY

-139.06%

Last updated:

Net Debt per Share of GemPharmatech Co is 2021 0.05 CNY. Net Debt per Share of GemPharmatech Co was 2020 -0.13 CNY. It decreases by -139.06% higher compared to the previous year.

The GemPharmatech Co Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-0.13 CNY
Jan 1, 2021
0.05 CNY
The GemPharmatech Co Net Debt per Share history
YEARNet Debt per ShareYoY
0.05CNY-139.06%
-0.13CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GemPharmatech Co Stock analysis

What does GemPharmatech Co do? GemPharmatech Co., Ltd. generates revenue through the research and development, manufacturing, and sale of experimental mouse models. The company utilizes gene-editing and other technologies to produce these models, which are primarily sold to satisfy experimental demands in gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental research areas. Customized model breeding, drug efficacy analysis, and model customization services are also key revenue streams, targeting institutions engaged in biomedical research and pharmaceutical development. The company's products and services are tailored for clients in the fields of gene function cognition, disease mechanisms analysis, and drug target discovery. These clients include research institutions and pharmaceutical companies requiring specialized mouse models for preclinical studies and drug development. The firm's focus on gene-editing technologies enables it to provide high-quality, customized solutions that meet specific research needs. GemPharmatech's business model centers on providing innovative solutions for experimental research through its proprietary gene-editing technologies. By offering both standard and customized mouse models alongside related services, the company addresses the growing demand for precise and efficient research tools in the pharmaceutical and biotechnology sectors. The firm's revenue streams are directly tied to the sale of these models and the provision of specialized services to clients in the biomedical research industry. GemPharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GemPharmatech Co stock

Net Debt per Share of GemPharmatech Co is 0.05 CNY in 2021.

Net Debt per Share of GemPharmatech Co changed from -0.13 CNY to 0.05 CNY, representing a -139.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share GemPharmatech Co since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — GemPharmatech Co

All Key Metrics — GemPharmatech Co